VC's new favorite guessing game: Who is Arfur Rock, the 'Gossip Girl of Silicon Valley?'
At a recent dinner for tech investors in San Francisco, venture capitalists discussed the usual industry gossip on deals before turning to a more nagging question: Who is behind the Arfur Rock X account?
"The guessing game was certainly going on," said Dylan Itzikowitz, a principal at South Park Commons who attended the dinner. "There are a lot of rumors about who he is."
Cloaked in anonymity, Rock is on a mission to bring more transparency to tech, as long it's good news.
Rock launched last year as a more serious, techie version of the popular Wall Street Litquidity account to serve up a steady diet of friendly leaks of unannounced funding rounds, confidential revenue numbers, and other insidery details.
Much of what Rock posts is the bread-and-butter scoops found in any tech publication, such as details on AI for call centers startup Cresta's Series D funding round or revenue numbers from voice AI platform ElevenLabs.
"They are like the Gossip Girl of Silicon Valley," said CC Gong, a principal at Menlo Ventures. "This has come up so many times with other VCs. Lots of people have theories."
Identifying only as an "anon GP at your favorite multistage-VC," Rock's account is named after Arthur Rock, the iconic early Silicon Valley investor behind Intel, Xerox, and Apple. The feed is decidedly niche, with just over 23,000 followers, though it has steadily been gaining fans.
"I mainly read it because it's an amazing account for nerding out about venture," said Jeff Weinstein, a partner at FJ Labs. "It's pretty cool to see granular data like this shared publicly."
"In an industry that runs on gossip, it's a breath of fresh air to have someone irreverent enough to be willing to anonymously air the laundry," said Will McKelvey, an investor at Lehrer Hippeau. "That said, it's only clean laundry."
For Rock, the effort to unmask his identity "is the least interesting question people ask me."
"If you pull apart the rose to see how it works, you ruin the rose," Rock wrote in an email responding to questions from Business Insider.
Most VCs BI spoke with demurred when asked who they think Rock is, but some offered broad theories.
"My best guess is an associate/VP level at a Bay Area growth firm," said Weinstein.
Jenny Fielding, cofounder and managing partner at Everywhere Ventures, suspects Rock is a junior associate at a large fund.
"If you're at a big firm, you're swapping deals with all the other associates at all the other firms," Fielding said. "They're the first eyes on all this stuff, so I don't think it's a super senior person."
Filling a void when startups are restricted
The Securities and Exchange Commission prohibits startups from publicizing when they are raising capital.
Please help BI improve our Business, Tech, and Innovation coverage by sharing a bit about your role — it will help us tailor content that matters most to people like you.
What is your job title? (1 of 2)
Entry level position
Project manager
Management
Senior management
Executive management
Student
Self-employed
Retired
Other
Continue
By providing this information, you agree that Business Insider may use this data to improve your site experience and for targeted advertising. By continuing you agree that you accept the Terms of Service and Privacy Policy .
"The SEC's primary concern is protecting unsophisticated or inexperienced investors from being swept up in the hype of an investment opportunity they don't fully understand or that lacks sufficient disclosure," said Steve Brotman, managing partner at Alpha Partners.
As a result, details about funding rounds are restricted to trusted circles, and founders might miss out on potential investors, Brotman said.
"What Arfur Rock is doing is essentially hacking the system," he said. "It enables fundraising information to leak anonymously."
Rock says the account's information comes from founders, investors, employees, limited partners, and anonymous tipsters, and anything posted is already a "known secret" in Silicon Valley.
"Everything I share has been passed around the right dinners, parties, group chats, etc," Rock said, adding that they would never violate a non-disclosure agreement. "I take this seriously. They're sacrosanct. If I'm under one, it is followed."
Although Rock posts nonpublic information, it is uniformly positive.
"You'll notice I don't post layoffs," Rock wrote. "I don't talk about firm departures. I don't talk about company scandals. I don't do down rounds. I don't share poor fund performances. I don't dunk on people. People constantly ask for or send me this kind of gossip. I want to spotlight some of what I consider the best among the current wave of companies — not criticize founders, investors, or my friends from behind a keyboard."
Is anonymity a feature or a bug?
Leaks are leaks, no matter how nice they may be, and some question whether Rock is providing as much of a public service as claimed.
Patrick Collison, CEO of Stripe, recently asked on X:"Do the companies consent to the leaks?" (Rock replied that people "are often surprised how much of what I share is green‑lit by the insiders themselves.")
Menlo Ventures' Gong said Rock's posts can sometimes upend startups' carefully laid publicity strategy.
"I'm all for transparency that helps founders," Gong said. "The downside is when the account leaks info before the founder is ready to announce, they don't get the press coverage they were hoping for."
Rock sometimes deletes posts without explanation, making it hard to track whether the posts are always accurate. Their mission of transparency is very much a one-way street, which Jay Kolbe, cofounder and senior managing partner of strategic communications firm Impact Partners, finds concerning.
"The downside of Arfur Rock isn't that it's opening a new channel for information, it's that we don't know the motives of those who are behind it," he said. "No matter how well-intended they may be, it lacks the necessary guardrails of proven channels and real reporting."
Jesse Middleton, general partner at Flybridge Capital Partners, says he finds Rock's account "fascinating" but takes the information with a grain of salt.
"There's no clarity on who's running the account (and no, I don't know), how reliable the data is, or whether there's any inherent bias," Middleton said.
Rock sees anonymity as a feature, not a bug, and seems to relish being a topic of conversation and intrigue.
"I think the ecosystem wins on balance when more insiders can share alpha and ideas freely, untethered from their public identities," they said. "The anonymity strips away any sense of bias and, frankly, the mystery keeps it interesting."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Business Insider
an hour ago
- Business Insider
New economic data has reignited Trump's fight with the Fed over cutting interest rates
Hello. An Air India Boeing 787 bound for London crashed soon after takeoff from the city of Ahmedabad, India, this morning. More than 240 people were on board the plane, according to India's Directorate General of Civil Aviation. We are following this developing story here. In today's newsletter, new economic data is reinvigorating the administration's fight with the Fed to cut interest rates. What's on deck Markets: Former Goldman Sachs interns shared advice they'd give to the bank's newest crop. Tech: We picked 10 exciting AI agent startups from Y Combinator's spring batch. But first, what inflation? If this was forwarded to you, sign up here. The big story A call for cutsMay's consumer price index report rose only 2.4% compared to last year, a lower-than-expected bump that had the Trump administration calling for interest-rate cuts again. Economists predicted a 2.5% rise in inflation. Shelter, which has been a bit of a mess since the COVID pandemic, was also identified as the "primary factor" in the increase in inflation by the Bureau of Labor Statistics. Finally, core CPI, which doesn't include more volatile prices, rose only 0.1% compared to a 0.3% rise expectation. In short, it was a good day for anyone saying inflation is no longer a problem. Which brings me to JD Vance. The vice president bashed the Federal Reserve, posting on X that the central bank's refusal to cut rates is " monetary malpractice," writes BI's Jennifer Sor. Vance took a page out of his boss's playbook. Last week, President Donald Trump, emboldened by weak jobs data from ADP, took a shot at Fed Chair Jerome Powell's inaction. Of course, one key issue giving Powell pause is Trump's own doing. The president's tariffs are expected by many to drive inflation, forcing the Fed to reconsider cutting rates despite prices moving in the right direction. At the same time, Powell has previously said he can only work with the hard data when making rate-cut decisions. And if that remains the case, the numbers don't yet show tariffs being a problem. May's CPI report didn't indicate a major impact from tariffs. Prices fell last month for apparel, furniture, and cars despite those areas being viewed as potential victims of Trump's trade policies. For the first time this year, Americans are feeling less anxious about rising prices, writes BI's Christine Ji. Consumer sentiment might not seem important, but it is. The gap between the hard economic data and how consumers actually feel about the economy has been noticeable, as Jennifer and Christine have previously covered. (Granted, not everyone is feeling good. Two recent Fed reports showed small-business owners' pain and uncertainty over tariffs.) Ultimately, the Fed doesn't have to answer to Trump or the American people. Its focus is on keeping unemployment and inflation low. And the market doesn't see anyone forcing the Fed's hand yet. CME FedWatch has the probability of rates remaining unchanged next week at almost 100%. 3 things in markets 1. Internship advice from Goldman Sachs insiders. Three former Goldman interns who are now an associate, a VP, and a partner shared with BI words of wisdom for the firm's new class of 2,600 summer interns. Here's what they wish they had known at that age. 2. Avala Global's inflection point. In 2022, former Viking Global star Divya Nettimi founded Avala Global, becoming the first billion-dollar launch run by a woman. The firm has seen good performance and significant staff turnover. As it approaches its third anniversary, Nettimi told BI she believes Avala is exactly where it should be. 3. Apollo ditches the PE recruiting practice that angered Jamie Dimon. This year, Marc Rowan's $785 billion asset manager won't be interviewing new analysts for jobs that start in 2027. The memo came just days after JPMorgan said it'd fire any first-year bankers with a future-dated job. 3 things in tech 1. Apple finally explains why the new Siri is still M.I.A. At Apple's 2024 WWDC conference, the company introduced an AI-powered Siri, which was met with much fanfare. A year later, the new-and-improved Siri still isn't here. Recently, Apple exec Craig Federighi has been speaking candidly about the delay. TLDR: Apple wants to get it right. 2. Microsoft is working on a version of its AI Copilot for the Pentagon. In a recent blog written for government customers, the tech giant said the Microsoft 365 Copilot for DoD environments would be available as soon as this summer, writes BI's Ashley Stewart. It's unclear if this is the mystery customer that's close to adding one million Copilot users, but regardless, the deal would be a major win for Microsoft. 3. Y Combinator asked for AI agent startups. The startup community delivered. Of the 144 startups in YC's spring accelerator program, 70 build AI agents. BI dug through the cohort to find 10 of the most interesting agentic startups, from teaching an old robot new tricks to helping consumers apply for the best mortgage. 3 things in business 1. Whole Foods x Amazon = one big ol' fam-azon. Amazon is mounting a big reorg to bring the organic grocer, which it bought in 2017, into its core business. Whole Foods corporate staff will move under Amazon's employee programs, including performance reviews and pay structure, per a copy of a company memo obtained by BI's Eugene Kim. Here's the team leading it. 2. Two major breakthroughs in cancer research. At the world's biggest cancer conference, doctors gave standing ovations to two announcements that could change the game on cancer treatment and prevention. One suggested exercise could be a solution. 3. The British can't get enough of Chinese cars. BYD sales are booming in the UK, where there are no tariffs on Chinese EVs. It's a bad sign for Tesla, whose sales are plummeting there, because it shows BYD can quickly snap up market share in a straight fight. In other news Trump said he will set unilateral 'take it or leave it' tariffs on trading partners in the next two weeks. The rise of Ozempic has Americans chasing dubious muscle-building miracles. The man behind Netflix's 'Dept. Q' thinks the future of entertainment is … games. Victoria's Secret is cutting back on deals and discounts as tariffs hit its business. Disney and Universal say these images show how the AI tool Midjourney steals their famous characters. Central banks just can't get enough of gold. Sullivan & Cromwell's Trump team makes courtroom debut in effort to clear his 34-count criminal conviction. People are using their birth charts to figure out where to live. I was skeptical until I tried it. A consultant who helps law firms decide which software to buy explains why legal tech is in trouble. What's happening today Bilderberg Meeting between US and European political and business leaders is held in Stockholm. The Insider Today team: Dan DeFrancesco, deputy editor and anchor, in New York. Lisa Ryan, executive editor, in New York. Hallam Bullock, senior editor, in London. Grace Lett, editor, in Chicago. Akin Oyedele, deputy editor, in New York. Amanda Yen, associate editor, in New York. Ella Hopkins, associate editor, in London. Elizabeth Casolo, fellow, in Chicago.
Yahoo
5 hours ago
- Yahoo
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025
Data from the ongoing Phase 2a study shows a 100% disease control rate with 45% of patients with advanced cutaneous T-cell lymphoma achieving an objective response: One complete response, three partial responses, and five stable diseases in nine evaluable patients so far Robust immune activation supporting clinical activity observed Study continues to enroll patients; dose optimization phase to follow. LUND, SE / / June 12, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated positive data from the ongoing Phase 2a dose expansion study of BI-1808 monotherapy in cutaneous T-cell lymphoma (CTCL). The data will be presented in a poster at the European Hematology Association (EHA) 2025 congress, June 12-15 in Milan, Italy. As of the cut-off date May 15, 2025, data showed a 100% disease control rate in nine evaluable patients with CTCL. Forty-five percent of these patients achieved an objective response, with one patient achieving a complete response (CR), three achieving a partial response (PR), and five exhibiting stable disease (SD). Additionally, two patients with peripheral T-cell lymphoma (PTCL) were evaluable, of which one showed a PR, while the other showed SD. Overall, BI-1808 monotherapy demonstrates promising clinical activity and robust immune BI-1808 was well tolerated, with all treatment-related adverse events reported as mild or moderate (Grade 1-2). Notably, no Grade 3 or higher adverse events were observed. Transient disease flares, including skin peeling, erythema, and pruritus during the first weeks of treatment, were observed and shown to be associated with the BI-1808 immunologic mechanism. These flares coincide with regulatory T cell depletion and influx of CD8+ T cells into the skin, indicating on-target immune activation. Immunofluorescence multiplexing, starting at week 5, further confirmed increased CD8+ T cell infiltration and elevated granzyme B, supporting the drug candidate's mechanism of action. "These results reinforce the potential of BI-1808 as a novel immune-modulating therapy for CTCL," said Martin Welschof, Chief Executive Officer of BioInvent. "The early and sustained immune activation observed, combined with a favorable safety profile and 100% disease control rate, support the value of our anti-Tumor Necrosis Factor Receptor 2 (TNFR2) approach. We believe that these early Phase 2a data represent a meaningful milestone in our mission to deliver transformative therapies for difficult-to-treat patients, and we look forward to advancing BI-1808 into later-stage studies." Details of the poster:Title: Robust Single Agent Activity of BI-1808, a Tumor Necrosis Factor Receptor 2 (TNFR2) Blocker/Depleter, in Cutaneous T Cell Lymphoma (CTCL) PatientsSession Date and Time: June 13, 2025, 6:30-7:30 pm CESTSession Title: Poster Session 1Lead Author: Stefan K. Barta, University of Pennsylvania Hospital, Philadelphia, PA, USAAbstract Number: PF961 The poster will be posted to the Scientific Publications section of the company website ( ). The safety and preliminary efficacy of BI-1808 monotherapy are currently being evaluated in a sub-cohort (Part A) of the ongoing Phase 2a ( NCT04752826 ) study in patients with T-cell lymphomas, including CTCL. The study is expected to enroll 20 patients at a signal-seeking dose, after which a dose optimization phase is planned to be initiated. In April 2025, BioInvent received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for BI-1808 for the treatment of CTCL and in March 2025, Orphan Drug Designation was received from the same agency for BI-1808 in T-cell lymphoma (TCL). About BI-1808The anti-TNFR2 antibody BI-1808 is part of BioInvent's tumor-associated regulatory T cells (Treg)-targeting program. TNFR2 is particularly upregulated on Tregs of the tumor microenvironment and has been shown to be important for tumor expansion and survival, representing a new and promising target for cancer immunotherapy. BI-1808 is a first-in-class drug candidate in clinical development for the treatment of solid tumors and blood cancer. BI-1808 has shown single agent activity and excellent tolerability in an ongoing Phase 2a study and signs of efficacy and favorable safety profile in combination with pembrolizumab in the ongoing Phase 1/2a study. About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at . For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: International AB (publ)Co. Reg. No.: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release. This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-12 09:00 CEST. Attachments BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025 SOURCE: BioInvent International View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Major Company Giving Employees $1,000 LEGO Allowance
Companies will often give their employees perks and extra benefits. These can include discounts, free items and even vacations. One major company is offering a benefit to employees that has rarely been seen, but is sure to make those who work at other companies slightly jealous. Professional services firm Deloitte offers its employees an annual well-being subsidy of up to $1,000. Employees are allowed to use that subsidy on a variety of items, and recent guidelines have added "Legos and puzzles," according to Business Insider. The company has offered the subsidy for several years, and recently upped the amount from $500. It's offered to most partners and salaried workers at the company, but interns, contractors and those on a leave of absence aren't eligible. "Most of the responses are things like 'Lego?!?!? Finally!' or jokes about how they can now rationalize buying the coveted Millennium Falcon Star Wars Lego set," one employee told BI. Another employee was happy to see Legos added, and said that spending a few hours to build a set "is a great stress reliever." Many employees were reportedly happy that the company was thinking outside of the box when considering what employees could or would spend the subsidy on. The popular building bricks are just one of the new additions to the policy. Other items and categories added to the subsidy list this year include kitchenware and kitchen appliances, spa services, personal fans and ergonomic pillows. The subsidy is a great benefit for working at Deloitte, one of the biggest consulting firms in the world. The work is often demanding, with employees reporting that they work an average of 55 hours per week. "Since you are constantly changing projects and working with different leaders, achieving work-life balance is sadly always variable," one employee said while speaking to Women in Business. "Sometimes you get it, sometimes you really don't." Ernst & Young, another of the Big Four consulting and professional service firms, offers a similar subsidy that allows employees to purchase items like game consoles and mattresses. Deloitte had nearly 173,000 employees last year and generated over $33 billion in revenue. Major Company Giving Employees $1,000 LEGO Allowance first appeared on Men's Journal on Jun 12, 2025